Table 2

Oncolytic adenoviruses in combination cancer therapy*

Oncolytic strainTumor targetedEffectStudiesReference
Ad with ChemotherapyChemotherapy agent
dl1520 (ONYX-015) 5-FU + leucovorinMetastatic gastric carcinoma (liver)Modest shrinkagePhase II (72)
 Cisplatin + 5-FUSquamous cell carcinoma (recurrent)Improved anti-tumor responsePhase II (78 , 79)
 Doxorubicin or paclitaxelThyroidSynergistic in vitro (117)
 Cisplatin + paclitaxelLung (NSCLC)Synergistic in vitro (118)
 5-FU + cisplatin1) Squamous cell carcinoma (head/neck)1) Enhanced in vivo (119)
2) Ovarian2) Enhanced
 CisplatinSquamous cell carcinoma (head/neck)Enhanced in vivo (14)
 5-FU1) Squamous cell carcinoma (head/neck)Enhanced in vivo (14)
2) colon
 CV787 Paclitaxel or docetaxelProstateSynergistic in vitro/in vivo (81)
 CV890 DoxorubicinLiverSynergistic in vitro/in vivo (37)
Ad with Radiation TherapyRadiation dose
 Ad FGR (Ad5-CD/TKrep) 50–74 GyProstateEnhancedPhase I (85)
 8–10 GyCervicalEnhanced in vivo (95)
 0–6 GyGliomaEnhanced in vitro (94)
 0–6 GyProstateEnhanced in vitro (94)
dl1520 (ONYX-015) 5 Gy (total body irradiation)GliomaEnhanced in vivo (82)
 2 or 20 GyColonEnhanced in vivo (13)
 0–6 GyThyroidEnhanced in vitro/in vivo (120)
 Ad5Δ24RGD 3 Gy in vitroGliomaEnhanced in vitro/in vivo (86)
 5 Gy in vivo
 CV706 10 GyProstateSynergistic in vitro/in vivo (87)
Ad with Gene TherapyGene
 Ad Ig.Ad5E1+E3TK Thymidine kinaseGliomaEnhanced in vivo (89)
 Ad.TKRC Thymidine kinaseColon, cervical, melanomaEnhanced in vivo (84)
Lung, ovarianMixed or no effect in vivo (90)
 Ad.wt.TK Thymidine kinaseLungNo effect in vivo (92)
 Ad FGR Cytosine deaminaseProstate, gliomaEnhancedPhase I, in vitro/in vivo (85)
 (Ad5-Cd/TKrep) Thymidine kinase
 Ad.DF3-E1/CMV-TNF TNF-αBreastEnhanced in vivo (92)
 Ad5/IFN Interferon consensusBreastEnhanced in vivo (98)
 Ad-HE HSP70PanEnhanced in vitro/in vivo (100)
dl1520-CE CarboxylesterasePanEnhanced in vivo (97)
 AdDelta24-p53 P53PanEnhanced in vitro (102)
  • * Revised and reprinted with permission from Ref. 1 .